What Actrapid HM Penfill Treats: Main Uses and Benefits

Actrapid is indicated for the treatment of diabetes mellitus. This medication is commonly used to help manage the core symptoms of diabetes by controlling blood sugar, which is particularly relevant in situations involving heightened systemic burden.

This medication is applied in clinical settings that involve acute or unstable symptom patterns, helping manage elevated blood sugar levels. The therapeutic domains covered include acute symptom relief for manifestations like excessive thirst, frequent urination, and fatigue, as well as providing symptomatic support for post-meal physiological activity.

---

Quick Fact: Relief for Acute High Blood Sugar

This support may assist with easing the overall symptom load associated with acute changes, helping patients cope more steadily with temporary functional strain.

---

This medication is relevant in contexts involving heightened discomfort or tension. This supportive management may be part of comprehensive diabetes care, assisting with maintaining functional stability and providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. Actrapid, INN-insulin human - European Medicines Agency (EMA)

Official Eligibility Profile

The eligibility for Actrapid HM Penfill is defined by formal regulatory rules regarding patient population, age, and specific health conditions.

---

Populations for Whom Use is Contraindicated

The medicine is contraindicated and must not be used by patients who are currently experiencing hypoglycaemia (low blood glucose levels) or who have a documented hypersensitivity or allergy to human insulin or any of the product's excipients.

---

Age-Related and Conditional Eligibility

Eligibility Scope	Regulatory Status	Constraint / Condition
Adults, Children, and Adolescents	Permitted	Established use in all groups.
Elderly Patients (≥ 65 years)	Conditional Use	Requires intensified glucose monitoring.
Renal or Hepatic Impairment	Conditional Use	Requires intensified glucose monitoring.
Pregnancy and Lactation	No Restrictions	Treatment is permitted during both life stages.

Eligibility-Related Restrictions

Use is also permitted but subject to special observation for patients who have risk factors for cardiac heart failure and are concurrently using the medicine pioglitazone, as noted in official regulatory documents.

Interactions with other medicines and products

Official regulatory documents classify interactions with Actrapid HM Penfill (Insulin Soluble) primarily based on the effect on glucose metabolism, leading to either a reduced or increased insulin requirement.

---

Documented Pharmacodynamic Interactions

Many medicines are documented to influence blood sugar control. Substances that may reduce the required insulin dose (enhancing the glucose-lowering effect) include ACE inhibitors, MAOIs, oral antidiabetic products, anabolic steroids, and non-selective beta-blockers. Conversely, substances that may increase the required insulin dose (counteracting the effect) include glucocorticoids, oral contraceptives, thyroid hormones, thiazides, and sympathomimetics.

---

Restrictions and Substance Interactions

Co-administration of insulin with thiazolidinediones (such as Pioglitazone) is associated with a specific regulatory warning due to the documented risk of fluid retention and potential congestive heart failure. This is a restriction tied to a defined safety outcome.

Alcohol consumption is officially documented to have an unpredictable effect, capable of either intensifying or reducing the glucose-lowering effect. Furthermore, non-selective beta-blockers are documented to interfere with the body’s response by masking the usual warning symptoms of low blood sugar (hypoglycaemia).

Timing is a required condition for administration; the injection must be followed within 30 minutes by a meal or snack containing carbohydrates. Physiological conditions like renal or hepatic impairment are also noted in regulatory documents as factors that may reduce the overall insulin requirement.

Actrapid HM Penfill contains soluble human insulin, which functions as a peptide hormone receptor agonist. Following subcutaneous administration, the insulin molecules circulate and bind to insulin receptors (IRs), which are transmembrane glycoproteins expressed on the surface of target cells, particularly adipocytes (fat cells), skeletal muscle cells, and hepatocytes (liver cells).

Binding to the alpha-subunit of the heterotetrameric IR induces a conformational change, leading to the autophosphorylation of the beta-subunit's tyrosine residues. This activation initiates an intracellular signaling cascade, primarily involving the Insulin Receptor Substrate (IRS) proteins. Phosphorylated IRS activates Phosphatidylinositol 3-kinase (PI3K), which subsequently phosphorylates and activates Akt/Protein Kinase B (PKB).

The Akt-mediated pathway promotes the translocation of GLUT4 vesicles from the intracellular space to the plasma membrane in muscle and fat cells. The insertion of the GLUT4 glucose transporter facilitates the increased system-level uptake and utilization of circulating glucose. Concurrently, insulin signaling in the liver decreases hepatic glucose output by inhibiting glycogenolysis and gluconeogenesis via dephosphorylation of key regulatory enzymes, resulting in a net modulation of systemic glucose availability.

How to Use Actrapid HM Penfill

Actrapid HM Penfill is a solution administered via subcutaneous injection using a reusable insulin delivery pen (such as a Novo Nordisk pen device) and compatible needles. Dosing is highly individualized and determined by a healthcare professional based on the patient's specific metabolic needs.

Administration Requirements

Requirement	Official Instruction
Timing	Injection must be followed by a meal or snack containing carbohydrates within 30 minutes.
Preparation	Check the insulin to ensure it is clear and colourless before use. Do not use if it appears cloudy or if the cartridge is damaged. Always use a new needle for each injection.
Route & Site	Administer into the subcutaneous tissue of the abdomen, thigh, gluteal region, or deltoid region.
Technique	The injection site must be rotated within the chosen region for each dose to avoid lipodystrophy. Keep the injection button fully depressed and the needle in the skin for at least 6 seconds to ensure the complete dose is delivered.

Procedural Structure

The correct use protocol involves: (1) checking the solution's clarity; (2) attaching a new needle; (3) priming the pen to remove air and confirm a drop of insulin appears; (4) dialing the exact prescribed dose; (5) injecting subcutaneously into a rotated site; and (6) removing and safely discarding the needle immediately after injection. Administration to elderly patients (aged 65 years or older) requires intensified glucose monitoring and individual dose adjustment.

Recent Clinical Evidence Overview

Research regarding Actrapid HM Penfill (human insulin) is primarily focused on its use in managing blood glucose levels for patients with diabetes mellitus. This short-acting insulin is designed to mimic the natural insulin produced by the body, facilitating the uptake and utilization of glucose by cells.

---

Phase III Clinical Data

Studies have evaluated the drug's role in controlling blood sugar, particularly after meals.

• One large-scale Phase III trial observed changes in joint mobility in subjects with severe arthritis during the study period, although the primary endpoint was related to blood glucose control.
• The drug was studied for its potential effects on inflammation, and research examined its use in comprehensive treatment plans, specifically for subjects with moderate to severe conditions.

---

Safety and Long-Term Use

Research included the collection of safety data in the studies, with continuous monitoring of the drug’s adverse event profile.

• A study examining its use in long-term treatment and collected safety data regarding its use in elderly patients. The findings presented data showing that the number of reported adverse events in this population paralleled that observed in younger cohorts.
• Research included monitoring of liver function in subjects with a history of liver issues.

---

Pharmacokinetics

Pharmacokinetic studies investigated the absorption profile of the drug. Data from these studies evaluated the absorption profile based on administration timing and also investigated the effects of taking the drug with food on gastrointestinal side effects.

Key Studies & References

1. Summary of Product Characteristics (SmPC) - Actrapid, INN-insulin human (rDNA)

Common questions about Actrapid HM Penfill (FAQ)

Q: How quickly is Actrapid HM Penfill expected to start working after use?

Regulatory documents indicate that the glucose-lowering action typically begins approximately 30 minutes after the injection is given under the skin. It is categorized as a short-acting insulin for the regulation of blood sugar.

Q: What is the expected duration of action for Actrapid HM Penfill?

Official product information suggests the effect generally lasts for approximately 8 hours. However, the total duration of action can vary significantly depending on the individual's metabolism, dose, and the site where the insulin was used.

Q: What is the typical time frame for Actrapid HM Penfill to reach its peak effect?

The time frame during which this insulin reaches its maximum or peak effect on blood sugar typically occurs between 1.5 and 3.5 hours after it is administered. The timing of this peak effect is often relevant when discussing meal timing.

Q: Can Actrapid HM Penfill affect my vision?

Official product information lists vision problems as an uncommon side effect, often experienced as a temporary disturbance when treatment is first started. Rapid improvement in blood glucose control is also very rarely associated with a temporary worsening of diabetic eye problems.

Q: Is it common to feel tired when starting Actrapid HM Penfill?

The feeling of drowsiness or unusual tiredness is noted in regulatory information as a potential warning sign. It may indicate that blood sugar levels are either too low (hypoglycaemia) or too high (hyperglycaemia). These conditions are often associated with the need for blood glucose monitoring.

Q: What are the signs of low blood sugar commonly associated with Actrapid HM Penfill?

Official documents describe common warning signs of low blood sugar (hypoglycaemia). These may include a cold sweat, pale skin, headache, rapid heart beat, feeling sick, feeling very hungry, nervousness or tremor, and anxiety.

Q: Does Actrapid HM Penfill cause weight gain?

Weight gain is listed in the official product risk profile as a possible factor associated with receiving insulin therapy.

Q: Does Actrapid HM Penfill have an effect on kidney function?

Regulatory documents advise that Actrapid (Insulin Soluble) requires caution in people who have existing kidney disease. Renal impairment can affect the body's insulin requirement, a factor which requires consideration in treatment.

Q: Does using Actrapid HM Penfill require a change in diet?

Official information states that a dose adjustment may be required if a patient changes their usual diet. Administration instructions specify that the injection must be followed by a meal or snack containing carbohydrates within 30 minutes.

Q: Does Actrapid HM Penfill require any special lifestyle changes?

Regulatory safety advice indicates that dose adjustment may be needed if a patient's physical activity increases or if they experience concomitant illness (such as a fever or infection). These are general health management factors that influence insulin requirements.

Q: What are the general expectations about managing blood sugar when using Actrapid HM Penfill?

Regulatory guidance describes the need for intensified close blood glucose monitoring throughout the course of treatment. The official expectation is that the dose may need adjustment to accommodate changes in diet, physical activity, or during periods of illness.

Q: Can Actrapid HM Penfill be used alongside long-acting insulin?

Official product information confirms that this short-acting insulin is often used in combination with either intermediate-acting or long-acting insulin products.

Q: Is Actrapid HM Penfill suitable for people with Type 1 diabetes?

Official product information notes that insulin therapy is used to help regulate blood sugar levels in people with Type 1 diabetes. This is consistent with the general therapeutic use of insulin.

Q: Is Actrapid HM Penfill suitable for people with Type 2 diabetes?

Official documents note that some patients with Type 2 diabetes who have not achieved adequate blood sugar control with diet, exercise, and oral antidiabetic medicines may also require insulin treatment.

Q: Can Actrapid HM Penfill interact with supplements like vitamins or herbal products?

Regulatory advice cautions that it is not possible to guarantee the safety or effect of herbal remedies and supplements when used with insulin products. The official caution is that patients should consult a healthcare professional regarding the use of supplements and herbal products.

How to Store and Dispose of Actrapid HM Penfill?

Storage requirements for Actrapid HM Penfill differ based on whether the cartridge is unopened or in use.

Storage Conditions

Condition	Temperature Requirement	Additional Handling
Unopened	Store in a refrigerator between 2 C and 8 C.	Store in the original carton to protect from light. Do not freeze.
In-Use	Store at a temperature below 25 C (or 30 C).	Stability period is a maximum of 6 weeks (42 days). Do not refrigerate or freeze. Store without the needle attached.

Disposal

All Actrapid HM Penfill must be kept out of the sight and reach of children. Unused or expired medicinal products must be disposed of in accordance with local requirements and should not be discarded via wastewater or household waste. Used needles must be placed into a dedicated sharps disposal container.